Wake Forest University Health Sciences: Myelodysplastic Syndromes trials
The registry lists 12 Myelodysplastic Syndromes studies with Wake Forest University Health Sciences as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 2Phase 2 7No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
- CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous TherapyTerminatedNCT01902381Phase 2Results posted
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
- T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
- Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00398047Phase 2Results posted
- CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic SyndromeWithdrawnNCT03929211Phase 1/2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00104806Phase 2
- Cholecalciferol in Treating Patients With Myelodysplastic SyndromeCompletedNCT00068276Phase 2